The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Recent advances in the CLL treatment landscape
In this video, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some insights into the treatment landscape of chronic lymphocytic leukemia (CLL), highlighting the important role of Bruton’s tyrosine kinase (BTK) inhibitors and venetoclax, as well as emerging treatment options for patients who progress after these therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
